LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a

LivaNova PLC (LIVN) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, LivaNova PLC (LIVN) trades at a P/E ratio of 22.5×. Over the past ten years it has ranged from 0.0× (March 2026) to 1,073× (October 2023); the current reading is higher than 82% of that period. That is in line with the Medical Devices industry median of 23.2× and in line with the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 39.9× (74.72%)
FY2023 158× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 23.8× (26.13%)
Mar 2026 32.3× —
Dec 2025 0.0× —
Sep 2025 0.0× —
44 more quarters

Against its own ten years

Low 0.0× High 1,073×
Ten-year median 0.0×
Current reading's percentile 82

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on LIVN